Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study

The objective of this study was to investigate the safety, tolerability, and pharmacokinetics of oral voriconazole in subjects at high risk of developingfungal infections. This was a multicenter, randomized, double-blind, double-dummy, parallel-group, dose escalation study with a fluconazole active control. Twenty-four subjects with hematological malignancies, solid tumors, or autologous bone marrow transplants were randomized to receive voriconazole 200 mg q 12 h (n = 9), voriconazole 300 mg q 12 h (n = 9), or fluconazole 400 mg OD (n = 6)for a period of 14 days. Blood samples were taken for the assessment of voriconazole pharmacokinetics in plasma on Days 1 and 14. Using a 200 mg q 12 h dosing regimen, geometric mean voriconazole peak plasma concentrations (Cmax) were 904 ng/ml on Day 1 and 2996 ng/ml on Day 14. Geometric mean voriconazole exposure, as measured by the area under the curve within a dosing interval (AUCtau), was 4044 and 20308 ng x h/ml on Days 1 and 14, respectively. On Day 1, geometric mean Cmax and AUC were 1.80- and 1.94-fold higher in subjects receiving voriconazole 300 mg q 12 h than in those receiving 200 mg q 12 h. Similarly, on Day 14, geometric mean Cmax and AUC were 1.56- and 1.80-fold greater in the high-dose group. Although the confidence intervals are large, this trend suggests nonlinearity in pharmacokinetics with respect to dose as seen in healthy volunteers. The absorption of orally administered voriconazole was relatively rapid, with t(max) achieved in 1.7 to 3.0 hours. There was a mean 5.4- and 5.0-fold accumulation of voriconazole over the 14-day study period in the 200 mg and 300 mg q 12 h dose groups, respectively. Voriconazole was generally safe and well tolerated. Mild, reversible visual disturbances were the most commonly reported adverse event but were not associated with treatment discontinuation. No patient developed a breakthrough fungal infection. It was concluded that in this group of patients at risk of fungal infection, voriconazole pharmacokinetics was consistent with that reported in healthy volunteers.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. J. M. Bruggemann, N. M. A. Blijlevens, D. M. Burger, B. Franke, P. F. Troke, and J. P. Donnelly Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients J. Antimicrob. Chemother., November 22, 2009; (2009) dkp416v1. [Abstract] [Full Text] [PDF]

				D. Andes, A. Pascual, and O. Marchetti Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications Antimicrob. Agents Chemother., January 1, 2009; 53(1): 24 - 34. [Full Text] [PDF]

				S. Gencer, S. Ozer, G. Demirhan, O. Ak, and A. Batirel Angio-oedema as an unusual tolerable side effect of voriconazole therapy J. Med. Microbiol., August 1, 2008; 57(8): 1028 - 1031. [Abstract] [Full Text] [PDF]

				A C Pasqualotto, M Shah, R Wynn, and D W Denning Voriconazole plasma monitoring Arch. Dis. Child., July 1, 2008; 93(7): 578 - 581. [Abstract] [Full Text] [PDF]

				S. B. Yanni, P. P. Annaert, P. Augustijns, A. Bridges, Y. Gao, D. K. Benjamin Jr., and D. R. Thakker Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes Drug Metab. Dispos., June 1, 2008; 36(6): 1119 - 1125. [Abstract] [Full Text] [PDF]

				M. L. Goodwin and R. H. Drew Antifungal serum concentration monitoring: an update J. Antimicrob. Chemother., January 1, 2008; 61(1): 17 - 25. [Abstract] [Full Text] [PDF]

				A. Freifeld, S. Arnold, W. Ooi, F. Chen, T. Meyer, L. J. Wheat, M. Smedema, A. Lemonte, and P. Connolly Relationship of Blood Level and Susceptibility in Voriconazole Treatment of Histoplasmosis Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2656 - 2657. [Full Text] [PDF]

				C. Eiden, H. Peyriere, M. Cociglio, S. Djezzar, S. Hansel, J.-P. Blayac, D. Hillaire-Buys, and for the Network of the French Pharmacovigilance Ce Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database Ann. Pharmacother., May 1, 2007; 41(5): 755 - 763. [Abstract] [Full Text] [PDF]

				A. Pascual, V. Nieth, T. Calandra, J. Bille, S. Bolay, L. A. Decosterd, T. Buclin, P. A. Majcherczyk, D. Sanglard, and O. Marchetti Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods Antimicrob. Agents Chemother., January 1, 2007; 51(1): 137 - 143. [Abstract] [Full Text] [PDF]

				J. Smith, N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1570 - 1572. [Abstract] [Full Text] [PDF]

				K. Tan, N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities J. Clin. Pharmacol., February 1, 2006; 46(2): 235 - 243. [Abstract] [Full Text] [PDF]

				M. J. Linares, G. Charriel, F. Solis, F. Rodriguez, A. Ibarra, and M. Casal Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods J. Clin. Microbiol., January 1, 2005; 43(1): 250 - 253. [Abstract] [Full Text] [PDF]

				T. J. Walsh, M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, et al. Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2166 - 2172. [Abstract] [Full Text] [PDF]